Results 41 to 50 of about 16,223 (208)

Clinical features of supranuclear palsy

Бюллетень сибирской медицины, 2009
Progressive supranuclear palsy related to neurodegenerative diseases of the brain. In the pathological process involved, and stem structure. The disease manifests a combination of progressive akinetic-rigid syndrome and early development of postural ...
T. A. Valikova, V. M. Alifirova, N. V. Pugachenko, R. B. Tsyrenzhapova, A. B. Bichik   +4 more
doaj   +1 more source

Stage‐Dependent β‐Synuclein Links MRI and Cognitive Decline in Alzheimer's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Synaptic degeneration drives cognitive decline in Alzheimer's disease (AD), but synaptic biomarkers are scarce. Brain‐enriched β‐synuclein emerged as a synaptic damage marker. We investigated its diagnostic, prognostic, and structural correlates across the AD continuum.
Ulaş Ay, Merve Alaylioglu, Erdi Sahin, Sanem Sultan Yoruk Oner, Gulce Iskan, Gulce Cosku Yilmaz Cakan, Gozde Kizilates‐Evin, Emre Hari, Elif Kurt, Erdinc Dursun, Basar Bilgic, Hasmet Hanagasi, Hakan Gurvit, Tamer Demiralp, Duygu Gezen‐Ak, Bedia Samanci   +15 more
wiley   +1 more source

Immunotherapy in progressive supranuclear palsy

Current Opinion in Neurology, 2020
Purpose of review Progressive supranuclear palsy (PSP) is a progressive adult-onset neurodegenerative disease. Abnormally, phosphorylated forms of the microtubule-associated protein tau containing four repeat domains (4R-tau) aggregate in neurons. Additionally, increasing evidence suggests that secretion and uptake of fragments
Pavan A, Vaswani, Abby L, Olsen
openaire   +3 more sources

Progressive supranuclear palsy: A case report and brief review of the literature

Radiology Case Reports
Atypical Parkinsonian syndromes are a subset of progressive neurodegenerative disorders that present with signs of Parkinson's disease. However, due to multisystem degeneration, the atypical Parkinsonian syndromes have additional symptoms that are often ...
Vivek Batheja, MD, Morgan Fish, DO, Aneri B. Balar, MD, Jeffery P. Hogg, MD, FACR, Dhairya A. Lakhani, MD, Musharaf Khan, DO   +5 more
doaj   +1 more source

Affective symptoms in progressive supranuclear palsy

Journal of Geriatric Mental Health, 2014
Progressive supranuclear palsy is an unusual neurodegenerative disorder, which superficially resembles Parkinson′s disease, and the initial manifestations are characterized by depression, akinesia and mild cognitive impairment.
K S Shaji, K S Jyothi
doaj   +1 more source

Label‐Free Myelin Fingerprinting: An Adult Human Post‐Mortem Brain Slice Platform via Coherent Anti‐Stokes Raman Spectroscopy

Advanced Science, EarlyView.
A serum‐free, air–liquid interface organotypic slice culture model preserves human post‐mortem corpus callosum tissue, successfully recovering from slicing trauma to reflect the donor's underlying disease state. Pairing label‐free Coherent anti‐Stokes Raman scattering (CARS) microscopy with k‐means clustering enables objective, high‐resolution ...
Kasra Roya‐Kouchaki, Jeroen P. Korterik, Femke Tjebbes, Geert J. Schenk, Herman L. Offerhaus, Antonio Luchicchi   +5 more
wiley   +1 more source

O‐GlcNAcylation Regulation of SNAP29‐Dependent Autophagy Activation Dictates Chemoresistance in Gastric Cancer

Advanced Science, EarlyView.
Model illustrating the proposed mechanism by which chemotherapy‐induced downregulation of OGT disrupts SNAP29 O‐GlcNAcylation, promoting STX17‐SNAP29‐VAMP8 SNARE complex assembly and protective autophagy, leading to chemoresistance, which in turn establishes a feedforward loop to perpetuate drug tolerance.
Liang Tang, Shaoji Zhao, Ziling Shao, Tao Luo, Baifu Peng, Yifan Liu, Jinning Ye, Jianjun Peng, Kaiyu Sun, Jianbo Xu   +9 more
wiley   +1 more source

Advances in diagnosis and treatment of progressive supranuclear palsy and interpretation of new diagnostic criteria

Chinese Journal of Contemporary Neurology and Neurosurgery, 2018
Recently, both the paper "Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches" in Lancet Neurol and "Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria" in ...
Jin-tai YU, Chen-chen TAN, Lan TAN
doaj  

Perivascular Spaces as Determinants of Amyloid, Tau, and Vascular Biomarker Progression

Annals of Neurology, EarlyView.
Objective Magnetic resonance imaging (MRI)‐visible enlarged perivascular spaces (PVS) are markers of cerebral small vessel disease (SVD) and aging, processes implicated in both neurodegenerative and cerebrovascular pathologies. However, longitudinal positron emission tomography (PET) studies examining PVS as a mechanism underlying Alzheimer's disease ...
Audrey Low, Jeffrey L. Gunter, Mingzhao Hu, Sheelakumari Raghavan, Scott A. Przybelski, Christopher G. Schwarz, Kejal Kantarci, Val J. Lowe, Ronald C. Petersen, Jonathan Graff‐Radford, Clifford R. Jack Jr, Prashanthi Vemuri   +11 more
wiley   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). I. Treatments in preclinical and early clinical development

Epilepsia, EarlyView.
Abstract Over the last 34 years, the Eilat Conference on New Antiepileptic Drugs and Devices has provided an interactive forum for stakeholders to discuss investigational and recently licensed treatments for seizures and epilepsy. The Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII) took place in Madrid, Spain, on May 3 ...
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source